Accessibility Menu
Gossamer Bio Stock Quote

Gossamer Bio (NASDAQ: GOSS)

$2.18
(-4.2%)
-0.10
Price as of October 21, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$2.18
Daily Change
(-4.2%) $0.10
Day's Range
$2.15 - $2.28
Previous Close
$2.18
Open
$2.27
Beta
1.63
Volume
2
Average Volume
3,764,322
Market Cap
495.7M
Market Cap / Employee
$2.18M
52wk Range
$0.66 - $3.6
Revenue
-
Gross Margin
0.93%
Dividend Yield
N/A
EPS
-$0.61
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Gossamer Bio Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
GOSS+136.7%-77.41%-25.73%-87%
S&P+15.06%+95.03%+14.29%+149%

Gossamer Bio Company Info

Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 25, 2015 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$11.49M-88.0%
Gross Profit$11.28M-88.1%
Gross Margin98.15%-0.8%
Market Cap$279.58M37.2%
Market Cap / Employee$1.93M0.0%
Employees1457.4%
Net Income-$38.27M-177.7%
EBITDA-$38.55M-172.6%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$26.31M-69.7%
Accounts Receivable$7.58M0.0%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$201.94M2.5%
Short Term Debt$0.89M-51.3%

Ratios

Q2 2025YOY Change
Return On Assets-45.17%-16.0%
Return On Invested Capital-64.38%4.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$47.11M0.0%
Operating Free Cash Flow-$47.06M-140.4%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book2.743.798.45-44.71-686.22%
Price to Sales2.121.792.006.95209.85%
Price to Tangible Book Value2.743.798.45-44.72-686.32%
Enterprise Value to EBITDA-3.04-3.23-5.33-6.99-725.72%
Return on Equity-90.3%-122.5%-500.6%-783.4%-9.27%
Total Debt$203.63M$202.88M$202.79M$202.83M1.99%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.